Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

Charles Flexner, Brian R. Murphy, James F. Rooney, Charles Wohlenberg, Vadim Yuferov, Abner L. Notkins, Bernard Moss

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
Issue number6187
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen'. Together they form a unique fingerprint.

Cite this